Prostate Cancer Coverage from Every Angle

Olaparib Approved by FDA for Metastatic HRR-Mutated Castration-Resistant Prostate Cancer

By: Jocelyn Solis-Moreira, MS
Posted: Friday, May 22, 2020

On May 19, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor olaparib (Lynparza) for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. In the United States, two FDA-approved companion diagnostic tests, FoundationOne CDX for HRR-gene alterations and BRACAnalysis CDX for BRCA1 and BRCA2 mutations, will be used to identify treatment eligibility.

The FDA approval was based on results from the prospective, multicenter, open-label phase III PROfound trial. Patients were divided into two cohorts based on their HRR-gene mutation status. Patients with BRCA1, BRCA2, or ATM mutations were randomly assigned to cohort A (n = 245); patients with mutations among 12 other genes involved in the HRR pathway were randomly assigned to cohort B (n = 142); and patients with co-mutations were assigned to cohort A.

In cohort A, the median radiologic progression-free survival was 7.4 months with olaparib versus 3.6 months with investigator’s choice of either enzalutamide or abiraterone acetate (hazard ratio [HR] = 0.34; 95% confidence interval [CI] = 0.25–0.47; P < .0001). In addition, the median overall survival was 19.1 months with olaparib versus 14.7 months without (HR = 0.69; 95% CI = 0.50–0.97, P = .0175). In cohorts A and B, the median radiologic progression-free survival with olaparib compared with enzalutamide or abiraterone acetate was 5.8 months versus 3.5 months (HR = 0.49; 95% CI = 0.38–0.63; P = .0001).

The most common adverse reactions in 10% or more of patients receiving olaparib included anemia, nausea, fatigue/asthenia, decreased appetite, diarrhea, vomiting, thrombocytopenia, cough, and dyspnea. In addition, venous thromboembolic events, including pulmonary embolism, occurred in 7% of patients in the olaparib arm compared with 3.1% of patients receiving enzalutamide or abiraterone.

The recommended olaparib oral dose is 300 mg twice daily, with or without food. For full prescribing information visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.